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Background: The tranradial intervention (TRI) has several advantages such as
reduction of bleeding risk, improvement of patients’ convenience, and immediate
ambulation as compared with the transfemoral intervention (TFI). In TRI, there are
some anatomical and technical differences between right and left radial approach. The
aim of this study is to evaluate the impact of the choice of the right or left radial
approach on 12 months clinical outcomes in patients undergoing TRI.
Methods: A total of 1,653 consecutive patients underwent TRI were enrolled from
Nov 2004 to Oct 2010 in Korean TRI Registry. The patients were divided into two
groups; right radial approach group (n¼792 pts) and left radial approach group
(n¼861 pts). To adjust potential confounders, propensity score matched (PSM)
analysis was performed using the logistic regression model (C-statistics: 0.726). After
PSM, total of 1,100 pts (550 pairs) were enrolled for this analysis.
Results: After PSM, the baseline clinical and angiographic characteristics were
balanced between two groups. However, contrast volume during procedure were
larger and ﬂuoroscopic time (22.5  28.0 min vs. 17.1  12.6 min) were longer in
right radial approach group (259.3  119.6 cc vs. 227.0  90.7 cc, p-value <0.001),
whereas procedure time (49.2  30.4 min vs. 55.4  28.7 min, p-value¼0.003)
were longer in left approach group. After PSM, procedural and in-hospital compli-
cations were similar between the two groups. The cumulative clinical outcomes up to
12 months including mortality, recurrent myocardial infarction (MI), repeat revascu-
larization, stent thrombosis and MACE were similar between the two groups (Table).
Conclusion: In this study, despite the procedural efﬁcacy including procedural time
and contrast volume were increased in right artery approach, however, 12 months
cumulative clinical outcomes were similar between the two groups.JACC Vol 63/12/Suppl S j April 22–25, 2014 j TCTAP Abstracts/LBCInnovative Devices and Futuristic Therapies
(TCTAP A-002)
TCTAP A-002
Paclitaxel-coated Balloon Versus Paclitaxel-eluting Stent for the Treatment of
Diffuse DES In-stent Restenotic Lesions: A Substudy of PEPCADChina ISR Trial
Ye-lin Zhao1, Bo Xu1, Jie Qian1, Jian-an Wang2, Shao-liang Chen3, Yue-jing Yang1,
Jun-bo Ge4, Run-lin Gao1
1Fu Wai Hospital, National Center for Cardiovascular Diseases, Beijing, China, 2The
Second Afﬁliated Hospital of Zhejiang University School of Medicine, Hangzhou,
China, 3Nanjing First Hospital, Nanjing Medical University, Nanjing, China, 4Fudan
University Zhongshan Hospital, Shanghai, China
Background: Treatment of drug-eluting stent in-stent restenosis (DES-ISR) is still
challenging especially in diffuse lesions. The intention of this subgroup analysis is to
compare the safety and effectiveness of paclitaxel-coated balloon (PCB) versus
paclitaxel-eluting stent (PES) in the treatment of patients with diffuse DES-ISR.
Methods: PEPCAD China ISR was a prospective, multicenter, randomized (1:1),
single blind trial conducted in China (n ¼ 220). There were 33 patients in PCB
(SeQuent Please, B.Braun Melsungen AG, Germany) group and 44 patients in PES
(Taxus LibertIJ, Boston Scientiﬁc, Natick, MA, USA) group with diffuse in-stent
restenotic lesions (Mehran type II-IV). All patients were required to undergo angio-
graphic follow-up at 9 months and clinical follow-up at 1 month, 6 months, 1 year,
and 2 years. The primary endpoint was in-segment late lumen loss (LLL) at 9 months.
Secondary endpoints included % diameter stenosis (DS), binary restenosis rate, and
target lesion failure (TLF), a composite of cardiac death, target vessel myocardial
infarction (MI) or ischemia-driven target lesion revascularization. In addition, deﬁnite/
probable stent thrombosis (ST) rates were documented.
Results: There were no signiﬁcant baseline differences between both treatment groups
in terms of patient, lesion or procedural characteristics. At 9 months, in-segment LLL
in the PCB group was comparable to the PES group (0.74 O 0.53 mm vs. 0.80 O
0.74 mm, p ¼ 0.69). The rates of 9-month in-segment binary restenosis, 12-month
TLF, composite of all cause death, all MI and any revascularization, and deﬁnite/
probable ST were no statistical differences between both treatment groups (27.3% vs.
32.4%, p ¼ 0.65; 21.2% vs. 15.9%, p ¼ 0.55; 27.3% vs. 29.5%, p ¼ 0.83; 3.0% vs.
0.0%, p ¼ 0.43, respectively).
Conclusion: Thepresent substudyoffers preliminary evidence thatDES-ISRpatientswith
diffuse lesions receiving PCB therapy were non-inferior to PES implantations. However,
current treatment options with either PES or PCB are not optimal for diffuse in-stent
restenotic lesions after DES failure. Further innovative therapies are needed to address this
kind of particularly difﬁcult patients. (ClinicalTrials.gov identiﬁer: NCT 01622075).
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Background: This study sought to compare the morphological characteristics and
underlying mechanism of paravalvular leak (PVL) after transcatheter aortic valve
implantation (TAVI) using the CoreValve (Medtronic, Santa Rosa, California) and the
Edwards valve (Edwards Lifesciences, Irvine, California).
Methods: A total of 68 TAVI patients (aged 84.27.4 years, Logistic EuroSCORE
21.512.4) who had pre and post-procedural multidetector computed tomography
(MDCT) were studied.
Results: In this cohort, 43 (63.2%) patients were treated with the CoreValve and the
remaining 25 (36.8%) patients received the Edwards valve. Post-TAVI eccentricity index
was signiﬁcantly higher inpatientsof theCoreValvegroup at each level of prosthesis (stent
bottom18.4 9.23 vs 5.2 4.0, p< 0.01, annulus level, 19.0 8.9 vs 5.8 7.8, p<0.01,
leaﬂet level 16.6 8.3 vs 4.5  3.5, p < 0.01). By multivariate analysis, only the Valve
Calciﬁcation Index (aortic valve calciﬁcation volume / body surface area) was identiﬁed as
independent predictor of any post-procedural PVL after CoreValve implantation (odds
ratio [OR] 1.002, 95% conﬁdence interval [CI] 1.000-1.004, p¼0.03). In patients with
Edwards valve, post-TAVI eccentricity index (leaﬂet level) was identiﬁed as an inde-
pendent predictor of post-procedural PVL (OR 1.31, 95% CI 1.02-1.68, p¼0.04).
Conclusion: Post-TAVI valve eccentricity was more frequently observed in Cor-
eValve implantation than after Edwards valve implantation. Valve eccentricity was
associated with PVL after Edwards valve implantation but not after CoreValve im-
plantation probably because of the supra-annular design of the CoreValve.T/Other (Unclassiﬁed) S1
